Testing a tailored radiation dose plan for liver tumors
Part of Cancer, Digestive system clinical trials.
This study compares a standard radiation dose plan versus a plan that adjusts the dose based on how the tumor responds to radiation-related measurements. It aims to improve how well stereotactic body radiation therapy (SBRT) treats liver cancer while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer or liver metastases that are confirmed by pathology (biopsy/surgery) or by specific scan features
- Your liver has 5 or fewer measurable lesions on a CT or MRI done within the last 90 days
- Your main liver tumor(s) are small enough overall to be 25 cm or less
- Your cancer cannot be removed by surgery (it’s considered unresectable) and you can safely receive radiation
- Your overall health is good enough (performance status 0–3) and you’re expected to live more than 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for liver cancer that can’t be removed with surgery: chemo through the liver (TACE) alone versus TACE plus a precise radiation treatment (SBRT). It may help people whose cancer stays in the liver but can’t be operated on, by testing whether adding focused radiation improves outcomes.
This trial tests a very high, single dose of radiation guided by MRI to destroy liver tumors that have spread from certain cancers. It may be a good option if you have 1 to 3 liver tumors that are away from sensitive organs and your liver is working well.
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
This study tests a focused type of radiation (SBRT) given after liver surgery to reduce the chance the cancer comes back, when the tumor was removed with a very small “safety margin.” It compares this approach to standard follow-up and looks at whether it improves outcomes in people with hepatocellular carcinoma.
This trial studies stereotactic body radiation therapy (high-precision radiation given in a few sessions) for liver metastases when surgery isn’t possible. It may help shrink or control tumors in the liver and delay progression in people whose cancer has not spread outside the liver (or only to areas treated with a curative plan).
This trial tests a single, high-dose radiation treatment (SBRT) guided by MRI for people with colorectal cancer that has spread to the liver. The goal is to see if this precise, one-time treatment can effectively control liver tumors while protecting nearby organs.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.